Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 7213 participants.

Also called NCT02313909

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 7,213 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02313909
  • EudraCT 2013-000768-27
Other papers using this trial's data
  • Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial Stroke, 2019-11 DOI, PubMed 31526123
  • Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial JAMA neurology, 2020-10-01 DOI, PubMed 32628266, PMC7550970 PubMed links an erratum for this paper. Erratum: PMID 32897298 Not in the PMC Open Access subset.
  • Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018-06 DOI, PubMed 29525076, PMC6701183 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis Stroke, 2019-09 DOI, PubMed 31401971
  • Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial Stroke, 2022-01 DOI, PubMed 34538089
  • Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial Stroke, 2020-07 DOI, PubMed 32517582
  • High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source Stroke, 2020-08 DOI, PubMed 32640945
  • Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial JAMA neurology, 2021-12-01 DOI, PubMed 34694346, PMC8546621 Not in the PMC Open Access subset.
  • Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial JAMA neurology, 2021-01-01 DOI, PubMed 33074284, PMC7573796 PubMed links an erratum for this paper. Erratum: PMID 33252627 Not in the PMC Open Access subset.
  • Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial Stroke, 2020-06 DOI, PubMed 32295509
  • Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source The New England journal of medicine, 2018-06-07 DOI, PubMed 29766772
  • Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy International journal of stroke : official journal of the International Stroke Society, 2022-08 DOI, PubMed 34791941, PMC9358304 In the PMC Open Access subset under CC BY-NC.
  • Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial European journal of neurology, 2020-05 DOI, PubMed 32056346

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Mexico, Poland, Portugal, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Türkiye, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02313909. Randomized; quadruple masking; primary purpose prevention. Start 2014-12-23 (actual); primary completion 2018-02-15 (actual). Results posted on 2019-01-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Acronym
NAVIGATE ESUS
Condition
Stroke
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939)
Intervention (Drug)
Acetylsalicylic acid (Aspirin, BAY1019036)
Intervention (Other)
Rivaroxaban-Placebo
Intervention (Other)
Aspirin-Placebo
Lead sponsor
Bayer (class: industry)
Collaborator
Janssen Research & Development, LLC (class: industry)
Collaborator
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct02313909
Content hash
ecf0dac72bd2930f7564479050048bfc92156be4d1098de36fdd4449ca05ed85